Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041839 | 1.00 | CYP2A6 (0.43) | CYP2A6TDP1ALDH1A1PKMAURKB | |
| SCHEMBL1752831 | 0.83 | SMARCA2 (0.59) | CYP2A6TDP1ALDH1A1PKMCASP1 | |
| SCHEMBL4867807 | 0.83 | AHR (0.42) | TDP1KDRCASP1KMT2ASMN1; SMN2 | |
| SCHEMBL3024901 | 0.82 | TDO2 (0.45) | SMN1; SMN2NPC1RAB9ATP53TSHR | |
| SCHEMBL1752937 | 0.81 | CSNK1D (0.47) | CYP2A6ALDH1A1CSNK1DSMN1; SMN2L3MBTL1 | |
| SCHEMBL2646929 | 0.81 | CASP1 (0.41) | TDP1ALDH1A1PKMCASP1SMN1; SMN2 | |
| SCHEMBL30453161 | 0.81 | CASP1 (0.41) | TDP1ALDH1A1PKMCASP1SMN1; SMN2 | |
| SCHEMBL25230310 | 0.79 | CYP1A2 (0.47) | CYP2A6TDP1ALDH1A1AURKBPLK4 | |
| SCHEMBL531767 | 0.79 | SMARCA2 (0.66) | CYP2A6TDP1ALDH1A1PKMSMARCA2 | |
| SCHEMBL526496 | 0.79 | SMARCA2 (0.46) | CYP2A6ALDH1A1CASP1SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129986-B1 | SUBSTITUTED PYRIDAZINE COMPOUND | TENVIE THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-112055711-B | Cyclohexylic acid triazolazine as LPA antagonist | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4269409-A1 | AMIDE OXAZOLE COMPOUND | Medshine Discovery Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-111909137-B | Pyridazinone derivative and application thereof | 深圳微芯生物科技股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230107277-A1 | SUBSTITUTED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-1379250-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002083675-A2 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083064-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6444666-B1 | SUCH AS ALZHEIMER'S DISEASE; SUBSTITUTED 1,2,4-TRIAZOLO(4,3-B) PYRIDAZINE DERIVATIVES ARE LIGANDS FOR GABA RECEPTORS; CONVULSANT ACTIVITY IS REDUCED OR ELIMINATED | MERCK SHARP & DOHME LTD. (GB) | 2002-09-03 | — | — | US | disclosed |
| EP-1150983-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-11-07 | — | — | EP | disclosed |
| US-6297235-B1 | ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | disclosed |
| EP-1107967-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000047582-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000012505-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | CYP2A6 2379/4885TDP1 581/4885ALDH1A1 3330/4885 |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | HTT, HYPK, FH | CYP2A6 1275/4885TDP1 384/4885ALDH1A1 1719/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | CYP2A6 2543/4885TDP1 652/4885ALDH1A1 3049/4885 |
| US-20230107277-A1 | SUBSTITUTED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | CYP2A6 2319/4885TDP1 478/4885ALDH1A1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.